Skip to main content

Table 3 Treatment-dependent difference in core outcome measures used to assess disease activity in rheumatoid arthritis (RA)

From: Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

Parameter, % change from baseline to week 8 ACR50 Patients
Tocilizumab Methotrexate
Responders Non-Responders Responders Non-Responders
DAS28% mean (CI-95%) − 54.7 (− 60.1 to −49.3) −30.0 (− 33.0 to − 27.0) −46.4 (− 52.1 to − 40.7) −12.8 (− 15.7 to − 10.1)
SJC, % mean (CI-95%) − 78.4 (− 83.8 to − 73.0) −29.7 (− 37.6 to − 21.7) −80.7 (− 89.0 to − 72.5) −22.8 (− 32.1 to − 13.6)
TJC, % mean (CI-95%) −76.3 (− 80.7 to − 72.0) −25.8 (− 34.1 to − 17.5) −73.6 (− 81.4 to − 65.8) − 22.1 (− 30.1 to − 14.2)
VAS Pain, % mean (CI-95%) −7.7 (− 35.2 to 19.9) −10.5 (− 28.5 to 7.5) −40.8 (− 68.3 to − 13.4) −22.8 (− 36.6 to − 8.9)
  1. Table represent mean percentage change from baseline to week 8 for each respective parameter. DAS28 28-Joint Disease Activity Score, TJC tender joint count, SJC swollen joint count, VAS Pain visual analogue scale pain